Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Purevdorj B Olkhanud

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Methods in Enzymology|January 18, 2020
Complementary approaches to study NKT cells in cancerJay A Berzofsky, Purevdorj B Olkhanud, Masaki Terabe
Oncoimmunology|December 16, 2022
The role of NKT cells in gastrointestinal cancersJulian Burks, Purevdorj B Olkhanud, Jay A Berzofsky
Methods in Molecular Biology (Clifton, N.J.)|May 22, 2025
NKT Hybridoma Cell Stimulation Assays to Evaluate Glycolipid Specificity and ProcessingKumiko Nishio, Kevin S Hsu, Jay A Berzofsky, et al.
Brain, Behavior, and Immunity|June 13, 2009
Tregs utilize beta-galactoside-binding protein to transiently inhibit PI3K/p21ras activity of human CD8+ T cells to block their TCR-mediated ERK activity and proliferationDolgor Baatar, Purevdorj B Olkhanud, Valerie Wells, et al.
Transplantation and Cellular Therapy|February 8, 2022
Thrombospondin-1, Platelet Factor 4, and Galectin-1 Are Associated with Engraftment in Patients with Sickle Cell Disease who Underwent Haploidentical Hematopoietic Stem Cell TransplantationAhmad Shaikh, Purevdorj B Olkhanud, Arunakumar Gangaplara, et al.
Methods in Molecular Biology (Clifton, N.J.)|April 23, 2025
Dendritic Cell Cancer Vaccines: A Focused ReviewHoyoung M Maeng, Purevdorj B Olkhanud, Mary Black, et al.
Methods in Molecular Biology (Clifton, N.J.)|April 23, 2025
Dendritic Cell Cancer Vaccines: Clinical Production for Cancer ImmunotherapyHoyoung M Maeng, Purevdorj B Olkhanud, Mary Black, et al.
Scientific Reports|November 28, 2024
Adjuvants to the S1-subunit of the SARS-CoV-2 spike protein vaccine improve antibody and T cell responses and surrogate neutralization in miceWilliam Becker, Khadija Rebbani, Zhijian Duan, et al.
Oncoimmunology|June 19, 2025
Cancer cells accelerate exhaustion of persistently activated mouse CD4<sup>+</sup> T cellsMalgorzata Stachowiak, William J Becker, Purevdorj B Olkhanud, et al.
Journal for Immunotherapy of Cancer|July 2, 2024
Second-generation checkpoint inhibitors and Treg depletion synergize with a mouse cancer vaccine in accordance with tumor microenvironment characterizationWilliam Becker, Purevdorj B Olkhanud, Noriko Seishima, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Methods in Enzymology|January 18, 2020
Complementary approaches to study NKT cells in cancerJay A Berzofsky, Purevdorj B Olkhanud, Masaki Terabe
Oncoimmunology|December 16, 2022
The role of NKT cells in gastrointestinal cancersJulian Burks, Purevdorj B Olkhanud, Jay A Berzofsky
Methods in Molecular Biology (Clifton, N.J.)|May 22, 2025
NKT Hybridoma Cell Stimulation Assays to Evaluate Glycolipid Specificity and ProcessingKumiko Nishio, Kevin S Hsu, Jay A Berzofsky, et al.
Brain, Behavior, and Immunity|June 13, 2009
Tregs utilize beta-galactoside-binding protein to transiently inhibit PI3K/p21ras activity of human CD8+ T cells to block their TCR-mediated ERK activity and proliferationDolgor Baatar, Purevdorj B Olkhanud, Valerie Wells, et al.
Transplantation and Cellular Therapy|February 8, 2022
Thrombospondin-1, Platelet Factor 4, and Galectin-1 Are Associated with Engraftment in Patients with Sickle Cell Disease who Underwent Haploidentical Hematopoietic Stem Cell TransplantationAhmad Shaikh, Purevdorj B Olkhanud, Arunakumar Gangaplara, et al.
Methods in Molecular Biology (Clifton, N.J.)|April 23, 2025
Dendritic Cell Cancer Vaccines: A Focused ReviewHoyoung M Maeng, Purevdorj B Olkhanud, Mary Black, et al.
Methods in Molecular Biology (Clifton, N.J.)|April 23, 2025
Dendritic Cell Cancer Vaccines: Clinical Production for Cancer ImmunotherapyHoyoung M Maeng, Purevdorj B Olkhanud, Mary Black, et al.
Scientific Reports|November 28, 2024
Adjuvants to the S1-subunit of the SARS-CoV-2 spike protein vaccine improve antibody and T cell responses and surrogate neutralization in miceWilliam Becker, Khadija Rebbani, Zhijian Duan, et al.
Oncoimmunology|June 19, 2025
Cancer cells accelerate exhaustion of persistently activated mouse CD4<sup>+</sup> T cellsMalgorzata Stachowiak, William J Becker, Purevdorj B Olkhanud, et al.
Journal for Immunotherapy of Cancer|July 2, 2024
Second-generation checkpoint inhibitors and Treg depletion synergize with a mouse cancer vaccine in accordance with tumor microenvironment characterizationWilliam Becker, Purevdorj B Olkhanud, Noriko Seishima, et al.
Pageof 3